Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16
February 07 2023 - 8:00AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company
will hold a conference call and live webcast on Thursday, February
16, 2023, at 4:30 p.m. Eastern Time (ET) to review its 2022
financial results and provide a business update.
Those who would like to participate may access the live webcast
here, or register in advance for the teleconference here. The link
to the live webcast will also be available on the Investors &
News section of the Ascendis Pharma website at
https://investors.ascendispharma.com. A replay of the webcast will
be available on this section of our website shortly after
conclusion of the event for 30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon platform to build a leading, fully
integrated, global biopharma company focused on making a meaningful
difference in patients’ lives. Guided by its core values of
patients, science and passion, the company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark, and has
additional facilities in Heidelberg, Berlin and Munich, Germany;
Palo Alto and Redwood City, California; and Princeton, New Jersey.
Please visit www.ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding Ascendis’ future operations, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
(i) Ascendis’ ability to apply its TransCon platform to build a
leading, fully integrated global biopharmaceutical company, and
(ii) Ascendis’ use of its TransCon technologies to create new and
potentially best-in-class therapies. Ascendis may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Ascendis makes, including
the following: dependence on third party manufacturers,
distributors and service providers for Ascendis products and
product candidates; unforeseen safety or efficacy results in its
development programs or on-market products; unforeseen expenses
related to commercialization of any approved Ascendis products;
unforeseen expenses related to Ascendis’ development programs;
unforeseen selling, general and administrative expenses, other
research and development expenses and Ascendis’ business generally;
delays in the development of its programs related to manufacturing,
regulatory requirements, speed of patient recruitment or other
unforeseen delays; Ascendis’ ability to obtain additional funding,
if needed, to support its business activities; the impact of
international economic, political, legal, compliance, social and
business factors, including inflation and the effects on its
business from the worldwide COVID-19 pandemic and ongoing conflicts
such as that in the region surrounding Ukraine and Russia. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Ascendis’
business in general, see Ascendis’ Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission (SEC) on March 2,
2022 and Ascendis’ other future reports filed with, or submitted
to, the SEC. Forward-looking statements do not reflect the
potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments
that Ascendis may enter into or make. Ascendis does not assume any
obligation to update any forward-looking statements, except as
required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo and TransCon are trademarks owned by the Ascendis Pharma
Group. © February 2023 Ascendis Pharma A/S.
Investor Contacts:Tim LeeAscendis Pharma+1 (650)
374-6343tle@ascendispharma.comir@ascendispharma.com |
Media Contact:Melinda BakerAscendis Pharma+1 (650)
709-8875media@ascendispharma.com |
|
|
Patti BankICR Westwicke+1 (415)
513-1284patti.bank@westwicke.com |
|
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2023 to Apr 2024